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Bin Wu†, Caixing Sun†, Fang Feng†, Minghua Ge and Liang Xia*Abstract
Background: CD133 and Nestin, as the markers of cancer stem cells, have recently been reported frequently in the
pathogenesis and development of human gliomas. However, the prognostic role of CD133 and Nestin in gliomas
still remains controversial. In this study, we aimed to evaluate the association between the expression of CD133
and Nestin and the outcome of glioma patients by conducting a systematic review and meta-analysis.
Methods: We performed systematically electronic and manual searches through the database of Pubmed and
embase (until to December 25, 2014) for titles and abstracts which investigated the relationships between CD133
and Nestin expression and outcome of glioma patients. A systematic review and meta-analysis was executed to
generate Pooled hazard ratios (HRs) with 95 % confidence intervals (CIs) for overall survival (OS) and progression-free
survival (PFS).
Results: A total of 1,490 patients from 32 studies (13 articles) were included in the analysis. 19 studies and 13 studies
investigated correlation between CD133 expression or Nestin and survival in gliomas, respectively. Our results showed
that high CD133 expression in patients with glioma was associated with poor prognosis in terms of OS (HR 1.69;
95 % CI, 1.16–2.47; P =0.0060) and PFS (HR, 1.64; 95 % CI, 1.12–2.39; P = 0.010). In addition, high Nestin expression were
associated with worse OS (HR 1.751; 95 % CI, 1.19–2.58, p = 0.004) but has no significant association with PFS (HR 1.55;
95 % CI, 0.96–2.51, p = 0.074). Even more important, the results of the subgroup meta-analyses show that that high
CD133 expression was associated with worse prognosis in terms of OS and PFS in patients with WHO IV glioma but
not WHO II-III. On the other hand, Nestin high expression was associated with worse prognosis in terms of OS and
PFS in patients with WHO II-III glioma but not WHO IV.
Conclusion: High level of CD133 expression trends to correlate with a worse OS and PFS in glioma patients,
especially WHO IV gliomas and Nestin high expression trends to correlate with a worse OS in glioma patients
especially WHO II–III, revealing both the markers of cancer stem cells may as the potential pathological
prognostic markers for glioma patients.
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Glioma is the most common primary brain tumor with
the most grade malignancy, although in recent years
the diagnosis and treatment of gliomas have made great
progress, the prognosis of patients with glioma remains
poor [1]. There is an urgent need to find a reliable
marker to predict the prognosis of glioma, thereby
providing the basis for the choice of a reasonable indi-
vidualized treatment plan [2].
Cancer stem cell theory considers that the occur-
rence of tumors derives from some special cells, these
cells are called cancer stem cells with the similar
characteristics to embryonic stem cells, such as self-
renewing and unlimited proliferation, multi-directional
differentiation and anti-chemoradiotherapy and so on
[3, 4]. Due to these characteristics of cancer stem cells,
the traditional treatments, such as radiation and che-
motherapy, can not effectively remove the cancer stem
cells, the remaining tumor stem cells continue prolifer-
ation and differentiation, leading to tumor recurrence
[4, 5]. There are a variety of markers used to isolate
glioma stem cells, CD133 and Nestin are the most
commonly used two markers that are widely expressed
in various tumor cells, such as malignant glioma, liver
cancer, ovarian cancer, colon cancer, lung cancer, etc.
[6–11]. In recent years, a number of studies analyze
the relationship between the markers of tumor stem
cells CD133, Nestin and prognosis of patients with
glioma, but due to differences in research method,
sample size and the study population, the findings of
a single sample are difficult to extend to the entire
population and the obtained conclusions are inconsist-
ent. This study used Meta-analysis method to system-
atically evaluate the literatures on the relationship
between the expression of Nestin, CD133 that were
multiple markers involving glioma stem cells and the
prognosis of patients with glioma.
Materials and methods
Search strategy and study selection
A systematic literature search of the PubMed and Embase
databases was conducted on studies evaluating the effect
of the markers of cancer stem cells (CD133 and Nestin)
on glioma patient survival. Our search strategy included
terms (“Glioma” or “Glioblastoma”) and (“CD133 antigen”
or “AC133 antigen” or “prominin-1” or “PROML1” or
“Nestin”) and (“Survival” or “Mortality” or “Prognosis”).
The literature search was conducted in 25 December 2014
and updated in 5 January 2015. Furthermore, a manual
search of reference lists from the relevant original articles
and review articles was also performed for additional
relevant publications.
Two independent reviewers (Xia L and Wu B) inde-
pendently inspected all candidate articles. Discrepancieswere resolved by discussion. Studies that met all the
following inclusion criteria were included in the review:
(i) The diagnosis of glioma was made based on patho-
logical examination; (ii) The association of the expression
CD133 or Nestin with OS or PFS about gliomas was
reported; (iii) The study provided the direct estimation of
hazard ratios (HRs) and there was 95 % confidence inter-
vals (CIs), or the date could be calculated by p values and
other data reported. (iv) We included the studies with
the largest sample size if the same glioma patient popula-
tion were found to overlap among publications.
Definitions and data extraction
The OS (overall survival) was defined as the time inter-
val between the medical treatment and the death of
patient or the last follow-up. The PFS (progression free
survival) was calculated as the time interval between the
date of treatment and the detection of the tumor recur-
rence or death from any cause. Both two reviewers
independently carried out data extraction from including
studies and any discrepancies were resolved by discus-
sion between the two. The following data were extracted
from all including studies: the first author’s name, year
of publication, country, sample size, patient age, WHO
grade, detect method of CD133 or Nestin expression,
cut‑off level, follow up period, survival analysis and
prognostic outcomes (PFS and OS). Any discrepancies
were resolved through discussion amongst the authors.
Quality assessment of primary studies
Quality assessment of included primary studies was
independently executed by two reviewers (Xia L and Wu B)
using the Newcastle–Ottawa Quality Assessment Scale
(NOS). NOS scores of ≥6 were defined as high-quality
studies. Any disagreement was determined by joint
discussion.
Statistical analysis
All analyses were performed by using stata 12.0 statis-
tical software (Stata Corporation, College Station, TX,
USA). Hazard ratio (HR) and 95 % confidence intervals
(CI) were got directly from each study or from estima-
tion of Kaplan-Meier survival curves according to the
methods by Parmer et al. An HR less than one was
defined as a better prognosis in glioma patients with
IDH mutation, whereas an HR more than one indicated
a poor prognosis. We the most powerful one (multi-
variate analysis was superior to univariate analysis. And
the latter one weighted over unadjusted Kaplan-Meier
analysis) was chose, if several HR estimates were pre-
sented in the same study.
The heterogeneity of the included trials was assessed
by the Cochrane’s Q statistic for each meta-analysis. We
carried out both fixed-effects (Mantel–Haenszel method)
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and producted the pooled HRs. Thanks to a priory of
assumptions about the likelihood of heterogeneity across
primary studies, the random-effects model was chosen. In
addition, subgroup analyses were performed to investigate
the potential causes of heterogeneity according to study
country, sample size, patient age, follow-up period, detect
method of CD133 or Nestin expression, cut‑off level and
WHO grade.
Publication bias was first investigated by Funnel plots
and then performed for each of the pooled study groups
using the Begg’s test. All p values were two-sided and
the significance level was set at 5 %.
Results
The study inclusion procedure and study characteristics
The selection procedure of the eligible studies was pre-
sented in Fig. 1. In brief, a total of 1153 studies were
identified from our initial electronic search. Of these, we
eliminated 306 studies owing to overlapping data sets. Of
which, 847 abstracts were considered relevant and full
texts were reviewed in detail. By the end of the review 13
literatures on glioma [12–24] (9 CD133 and 6 nestin;
1,490 patients), meeting our inclusion criteria for meta-
analysis, were left with sufficient data for extraction.
The baseline characteristics of the literatures enrolled
were summarized in Tables 1 and 2. Thirty two studies
were included in those studies including 19 studies
investigated the association between CD133 expression
and outcome of glioma patients and 13 studies forFig. 1 Flowchart of study selectionNestin. All studies were published between 2008 and
2014. Of these, the majority of the studies were executed
in Europe (n = 23). Others were conducted in Asia (n = 8)
and USA (n = 1). The total sample size from all studies
was 1490 and the sample size was 24–379 patients and
the range of medium age was 37.5–60.1 years. Of which,
13 studies evaluated grade II–III gliomas and 17 examined
grade IV glioma. HRs and 95 % CI for OS or PFS in 27
studies could be directly extracted and was produced by
Kaplan-Meier analysis for the 5 remaining studies. The
most frequently used cutoff values for the high versus
low/ present versus absent expression of CD133 or Nestin
were the median (n = 15) and values calculated by using
several semiquantitative methods.
CD133 expression and OS in gliomas
A total of 11 studies were involved in the association
between CD133 expression and OS of glioma patients,
among which statistically significant heterogeneity was
observed (I2 = 77.8 %). Therefore, a random model was
applicable to calculate a pooled HR and 95 % CI, the
combined analysis showed that upon comparing patients
with a low expression of CD133, patients possessing
high CD133 expression had a significantly poorer OS
(HR = 1.69, 95 % CI: 1.16 to 2.47; P = .0006)(Fig. 2).
In order to avoid the influence of heterogeneity, fur-
ther subgroup analyses were conducted and stratified
based on the study origin, sample size, follow up period,
patient age, test method, cut‑off level and WHO grade.
And the results showed that almost the subgroup
Table 1 General characteristics of included studies (about the relationships between CD133 expression and OS or PFS in glioma patients)










Cut off level Survival
end points
Follow up period Survival analysis Adjusted variables
Ardebili [10] 2011 Slovenia 24 mean 60 IV QRT-PCR 30 000 (─, 2-
ΔΔCt > 30.000)
OS NR univariate (KM) NR
Kase [11] 2013 Estonia 42 30–77 IV IHC median OS NR multivariate Radiotherapy dose, Chemotherapy, Karnofsky
performance score
Kim [12] 2011 Korea 88 mean 54.9 (13–80) IV IHC 50 % OS mean 13.9 months
(1–53)
multivariate age, sex, Karnofsky performance scale (KPS)
score, extent of removal, chemoradiotherapeutic
modality, temozolomide modality, after
temozolomide therapy and stem cell marker
expression
PFS
Melguizo [13] 2012 Italy 75 24–81 IV IHC 25 % OS NR multivariate (KM) NR
PFS
Metellus [14] 2011 France 48 mean 60.1 ± 9.2 IV QPCR 1.03 OS Median 18.9 months multivariable Age, extent of surgery, MGMT status
(MethyLight)
PFS
Shibahara [15] 2013 Japan 112 Media 57 (7–77) IV WB CD133/b-actin
ratio = 1
OS Median 25.7 months
(3–152)
multivariable Ki67 LI (≥35 %), 9p homozygous deletion and
10q loss
Shin [16] 2013 Korea 67 NR IV IHC 50 % OS NR multivariable status
PFS
Zeppernik [17] 2008 Germany 48 NR II–III IHC 1 % OS mean 86 months
(±39)
multivariate age, WHO grade and extent of resection
PFS
Dahlrot [18] 2014 Denmark 25 NR II IF median OS Media 12 months multivariate age, performance status (PS) and IDH1 status
PFS
Dahlrot [18] 2014 Denmark 26 NR III IF median OS Media 12 months multivariate age, performance status (PS) and IDH1 status
PFS















Table 2 General characteristics of included studies (about the relationships between Nestin expression and OS or PFS in glioma patients)














Follow up period Survival analysis Adjusted variables
Hatanpa [19] 2014 USA 50 median 37.5 years
(20–66)
II–III IHC median OS 4.3 year multivariate (KM) nestin, IDH, WHO grade, oligodendroglioma
component (astrocytoma or oligoastrocytoma),
MIB-1, age, sex, extent of resection and type of
adjuvant, therapy
Milde [20] 2012 Russia 379 NR II–III IHC 50 % OS median 53 months multivariate cytogenetic group only, or cytogenetic
group and posterior fossa group
PFS
wan [21] 2011 Germany 283 NR II–IV IHC median OS Mean 11.21 ± 4.26 years multivariate WHO grade, patient age at diagnosis and
extent of resection
Kim [12] 2011 Korea 88 mean 54.9 years
(13–80)
IV IHC 50 % OS mean 13.9 (1–53) months multivariate age, sex, KPS, extent of removal,
chemoradiotherapeutic modality,
temozolomide modality, after temozolomide
therapy and stem cell marker expression
PFS
Arai [22] 2012 Japan 64 median 55 years
(11–79)
III–IV IHC 60 % OS 1–67 months KM NR
Dahlrot [18] 2014 Denmark 25 NR II IF median OS Media 12 months multivariate age, performance status (PS) and IDH1 status
PFS
Dahlrot [18] 2014 Denmark 26 NR III IF median OS Media 12 months multivariate age, performance status (PS) and IDH1 status
PFS














Fig. 2 A forest plot of HR and 95 % CI of the association between CD133 expression and OS of gliomas
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tic role of glioma in OS substantially. And, increased
expression of CD133 predicted a significantly worse
OS in following subgroups including sample size ≤ 50,
follow up period > media 12 months or no referred
median/mean age referred, IHC test and cut‑off level
not median. However, we did not discover any signifi-
cant association in other subgroups (Table 3). Even
more important, when in subtotal analysis stratified by
WHO grade of glioma, 8 studies of WHO IV glioma
exhibited a significant association between increased
expression of CD133 and poor OS (HR 1.73; 95 % CI,
1.20–2.50, p = 0.004 I2 = 76.3). While, we did not find
any significant association in subgroups of WHO II–III
giomas (HR 2.38; 95 % CI, 0.30–18.82, p = 0.441 I2 = 87.0).
Regarding the publication bias in the studies, we found
no funnel plot asymmetry. Furthermore, Begger’s test
was applied to provide statistical evidence for funnel plot
symmetry. As expected, the P value of Begger’s test was
0.350 (Fig. 3). Hence, there was no evidence for signifi-
cant publication bias in the meta-analysis.CD133 expression and PFS in gliomas
Eight studies provided information concerning the as-
sociation between CD133 expression and PFS of glioma
patients. Similarly, a random model was applicable to
calculate a pooled HR and 95 % CI, since significant
heterogeneity was observed in the pooled studies (I2 =
80.5 %). The combined analysis exhibited a significant
association between increased expression of CD133 and
poor PFS (HR 1.73; 95 % CI, 1.86–2.83, p = 0.027)
(Fig. 4).
Further subgroup analyses were conducted and strati-
fied based on the study origin, sample size, follow up
period, patient age, test method, cut‑off level and WHO
grade. And the results show that increased expression of
CD133 predicted a significantly worse OS in following
subgroups including sample size ≤ 50, follow up period >
media 12 months or no referred median/mean age re-
ferred, IHC test and cut‑off level not median. However,
we did not discover any significant association in other
subgroups (Table 3). Similarly, the results in subtotal
analysis stratified by WHO grade of glioma showed that
Table 3 Subgroup analyses of the relationships between CD133 ovexpression and overall survival or progression-free-survival
Comparison
variables









HR 95 % CI, P value Interaction,
P value
Total 11 (77.8) 1.69 (1.16–2.47), 0.006 NA 8 (68.2) 1.64 (1.12–2.39), 0.010 NA
Origin country
Europe 8 (81.0) 1.63 (1.03–2.61), 0.039 0.030 6 (76.5) 1.74 (1.06–2.83), 0.027 0.579
Asian 3 (42.5) 1.85 (1.02–3.35), 0.044 2 (0.0) 1.37 (0.86–2.18), 0.188
Sample size
>50 4 (77.4) 1.45 (0.91–2.31), 0.116 0.000 3 (0.0) 1.37 (1.01–1.73), 0.009 0.092
≤50 7 (67.6) 1.94 (1.07–3.54), 0.030 5 (77.0) 1.99 (0.94–4.22), 0.073
Follow up period
1,>media 12months 4 (74.1) 2.48 (1.13–5.45), 0.024 0.000 3 (86.7) 2.64 (0.98–7.11), 0.054 0.060
2,≤media 12months 3 (43.0) 0.90 (0.54–1.49), 0.678 3 (0.0) 1.12 (0.79–1.57), 0.530
3,No Referreed 4 (0) 2.11 (1.52–2.93), 0.000 2 (0.0) 1.64 (1.19–2.27), 0.003
Median/mean age y
Referred 6 (0.0) 1.85 (1.45–2.37), 0.000 0.000 3 (0.0) 1.59 (1.24–2.04), 0.000 0.713
No Referred 5 (79.8) 1.57 (0.70–3.55), 0.274 5 (80.8) 1.79 (0.81–3.97), 0.153
Test method
IHC 5 (64.8) 2.16 (1.25–3.73), 0.006 0.000 4 (80.9) 2.25 (1.11–4.58), 0.025 0.122
Others 6 (71.2) 1.37 (0.85–2.22), 0.202 4 (20.4) 1.31 (0.93–1.84), 0.122
Cut‑off level
1:median 4 (61.4) 1.09 (0.66–1.79) 0.748 0.000 3 (0.0) 1.12 (0.79–1.57), 0.530 0.024
2:others 7 (51.3) 2.17 (1.44–3.27), 0.000 5 (74.5) 2.07 (1.25–3.43), 0.005
WHO grade
IV 8 (76.3) 1.73 (1.20–2.50), 0.004 0.915 5 (0.00) 1.46 (1.19–1.80), 0.000 0.143
II–III 3 (87.0) 2.38 (0.30–18.82), 0.411 3 (88.1) 2.17 (0.42–11.28), 0.355
Fig. 3 A Begg’s funnel plot for the publication bias test of the CD133 or Nestin overexpression and OS or PFS of human gliomas
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Fig. 4 A forest plot of HR and 95 % CI of the association between CD133 expression and PFS of gliomas
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association between increased expression of CD133 and
poor OS (HR 1.46; 95 % CI, 1.19–1.80, p = 0.000 I2 =
0.00). However, we did not find any significant associ-
ation in subgroups of WHO II–III giomas (HR 2.17;
95 % CI, 0.42–11.28, p = 0.355 I2 = 88.1).
At the same time, no funnel plot asymmetry was
found in the studies and the Begger’s test did not show
any evidence of publication bias (P = 0.902; Fig. 3).Nestin expression and OS in gliomas
Eight eligible studies provided the estimation of the HR
and 95 % CI for the correlation between Nestin expres-
sion and OS of glioma patients, among which statisti-
cally significant heterogeneity was observed (I2 = 75.8 %).
Therefore, a random model was applicable to calculate a
pooled HR and 95 % CI and the combined analysis
showed that upon comparing patients with a low expres-
sion of Nestin, patients with high Nestin expression had
a significantly poorer OS (HR = 1.75, 95 % CI: 1.19 to
2.58; P = 0.004) (Fig. 5).The subgroup analyses were conducted and stratified
based on the study origin, sample size, follow up
period, patient age, test method, cut‑off level and
WHO grade. And the results showed that increased
expression of CD133 predicted a significantly worse
OS in following subgroups including sample size ≤ 50,
follow up period > media 12 months or no referred,
median/mean age referred, IHC test and cut‑off level
not median. However, we did not discover any signifi-
cant association in other subgroups (Table 4). Even
more important, when in subtotal analysis stratified by
WHO grade of glioma, four studies of WHO II–III gli-
oma exhibited a significant association between in-
creased expression of Nestin and poor OS (HR 3.11;
95 % CI, 1.45–6.67, p = 0.004 I2 = 57.2). However, we
did not discover any significant association in sub-
groups of WHO IV giomas (HR 1.09; 95 % CI, 0.83–
1.44, p = 0.518 I2 = 0.000).
The publication bias in the studies was conducted, the
funnel plot asymmetry was not found. Then, we applied
Begger’s test to provide statistical evidence for funnel
plot symmetry. As expected, the P value of Begger’s test
Fig. 5 A forest plot of HR and 95 % CI of the association between Nestin expression and OS of gliomas
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significant publication bias in the meta-analysis.
Nestin expression and PFS in gliomas
The combined analysis of the five studies did not exhibit
a significant association between increased expression of
Nestin and poor PFS (HR 1.55; 95 % CI, 0.96–2.51, p =
0.074) (Fig. 6).
Further subgroup analyses were conducted and strati-
fied based on the study origin, sample size, follow up
period, patient age, test method, cut-off level and WHO
grade. And the results showed that increased expression
of Nestin predicted a significantly worse OS in following
subgroups including sample size ≤ 50, follow up period >
media 12 months or no referred, median/mean age re-
ferred, IHC test and cut‑off level not median. However,
we did not discover any significant association in other
subgroups (Table 4). Similarly, the results in subtotal
analysis stratified by WHO grade of glioma showed that
two studies of WHO IV glioma exhibited a significant
association between increased expression of Nestin and
poor OS (HR 2.34; 95 % CI, 1.68–3.27, p = 0.000 I2 = 0.000).However, we did not find any significant association in sub-
groups of WHO II–III giomas (HR 1.04; 95 % CI, 0.77-1.41,
p = 0.808 I2 = 0.000).
At the same time, no funnel plot asymmetry was
found in the studies and the Begger’s test did not show
any evidence of publication bias (P = 0.221; Fig. 3).
Discussion
Cancer stem cells (CSC), a small portion of cell popula-
tion with the characteristics of stem cells, are present in
the tumor tissue. It is the root to form the tumor cells
with different degree of differentiation because of a cap-
acity of self-renewing and the multi-directional differen-
tiative potential [1, 3, 25]. At the earliest, CSC is found
in the blood system tumors [26]. Recently, with the de-
velopment of flow cytometry and in vitro tumor forma-
tion technology, cancer stem cells have been isolated
and identified in a variety of solid tumors [27, 28]. The
proposed cancer stem cell theory makes people have a
new understanding on the biological behavior of tumors:
the tumor is not only a genetic disease, but also a disease
of stem cells. Stem cells become cancer stem cells after
Table 4 Subgroup analyses of the relationships between Nestin expression and overall survival or progression-free-survival
Comparison
variables









HR 95 % CI, P value Interaction,
P value
Total 8 (75.8) 1.75 (1.19–2.58), 0.004 NA 5 (71.5) 1.55 (0.96–2.51), 0.074 NA
Origin country
Europe 5 (73.1) 1.52 (1.04–2.21), 0.029 0.014 4 (74.1) 1.76 (0.98–3.14), 0.057 0.142
Asian 2 (81.8) 1.92 (0.43–8.62), 0.393 1 (NA) 1.55 (0.96–2.51), 0.973
USA 1 (NA) 13.42 (2.56–70.34), 0.002
Sample size
>50 5 (71.6) 1.41 (1.00–1.98), 0.051 0.005 3 (82.6) 1.39 (0.77–2.50), 0.277 0.322
≤50 3 (71.2) 3.61 (0.99–13.17), 0.052 2 (36.5) 2.14 (0.85–5.35), 0.105
Follow up period
1,>media 12months 2 (68.7) 4.96 (1.08–22.78), 0.040 0.001 1 (NA) 2.40 (1.60–3.40), 0.000 0.008
2,≤media 12months 3 (68.8) 1.64 (0.74–3.67), 0.225 3 (55.4) 1.49 (0.76–2.94), 0.246
3,No Referreed 3 (66.8) 1.35 (0.77–2.38), 0.300 1 (NA) 1.01 (0.57–1.79), 0.973
Median/mean age y
Referred 3 (83.4) 3.36 (0.72–15.61), 0.123 0.154 1 (NA) 1.01 (0.57–1.80), 0.973 0.142
No Referred 5 (75.8) 1.52 (1.04–2.21), 0.029 4 (74.7) 1.76 (0.98–3.14), 0.057
Test method
IHC 5 (82.1) 2.11 (1.10–4.04), 0.025 0.671 2 (83.6) 1.60 (0.69–3.73), 0.275 0.063
Others 3 (68.8) 1.64 (0.74–3.67), 0.225 3 (55.4) 1.49 (0.76–2.51), 0.246
Cut‑off level
1:median 5 (74.1) 1.55 (1.00–2.42), 0.050 0.021 3 (55.4) 1.49 (0.76–2.94), 0.246 0.063
2:others 3 (75.6) 2.10 (0.88–5.00), 0.093 2 (83.6) 1.60 (0.69–3.73), 0.275
WHO grade
IV 2 (0.0) 1.09 (0.83–1.44), 0.518 0.000 2 (0.00) 1.04 (0.77–1.41), 0.808 0.000
II–III 4 (57.2) 3.11 (1.45–6.67), 0.004 3 (0.00) 2.34 (1.68–3.27), 0.000
Wu et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:44 Page 10 of 12gene mutations, which is the root of tumor recurrence
and metastasis [29].
Glioma stem cells can be sorted by finding its
markers in order to conducted the targeted chemo-
therapy for glioma stem cells, which can effectively
improve the specificity of chemotherapy and reduce
the side effects on the normal engine body and cells,
thereby finding a new breakthrough for cancer treat-
ment [30]. Recently, the markers of glioma stem cell
that are studied more than others include CD133,
nestin, HMGA1, A2B5, etc. [31–34]. It has made some
breakthroughs from the continuous in-depth study of
these markers, but there is a lot of controversy.
At present, a number of studies have shown that gli-
oma stem cell markers CD133 and Nestin are closely re-
lated to the prognosis of patients with glioma, but some
individual studies show that there is no clear relationship
between CD133, Nestin and the prognosis of patientswith glioma. We used Meta-analysis to systematically
evaluate the literatures on the relationship between the
glioma stem cells markers Nestin, CD133 and the prog-
nosis of patients with glioma in order to accurately and
objectively evaluate the application value of CDl33 and
Nestin in prognosis of glioma.
The current meta-analysis is the first to systematically
estimate the association between cancer stem cell
markers and glioma survival. In this study, the results
showed that CSCs marker CD133 was associated with
worse OS and PFS in glioma patients and Nestin was
associated with worse OS but not PFS. Especially,
subgroup analysis showed that the overexpression of
CD133 had a more significant predictive value for
glioma patients with WHO grade II–III, but Nestin for
WHO grade IV.
Limitations of this study include: (1) the number of
selected cases in the research is too few, especially only
Fig. 6 A forest plot of HR and 95 % CI of the association between Nestin expression and PFS of gliomas
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all the relevant data, the potential publication bias is
inevitable, some data may be missing. The missing infor-
mation may reduce the reliability of CDl33 and Nestin
expression as a prognostic indicator of glioma. (3)
Although immunohistochemistry and RT-PCR are the
detection methods for CDl33, Nestin protein and gene,
there are still some differences. This article collected all
relevant documents in protein and gene level, there may
be some heterogeneity in the methods. (4) the criterion
of positive decision for the selected CDl33 and Nestin is
different (median, mean, 25 %, 50 %, 1 %, or 3 others),
leading to the heterogeneity of studies. (5) Follow-up
time is different. So the study used a random effects
model and subgroup analysis to compensate for these
deficiencies.
Above all, we found that high CDl33 expression may
be independent risk factor for glioma patients’ progno-
sis, especially WHO IV gliomas and high Nestin ex-
pression may be independent risk factor for glioma
patients’ prognosis with grade WHO II–III. Based on
the current findings, assessing CDl33 and Nestin ex-
pression could provide better prognostic informationfor patients with glioma and be used as a novel thera-
peutic target. Further large-scale cohort studies are
needed to validate our results.
Competing interests
All the authors declare that they have no competing interests.
Authors’ contributions
WB, SC and FF carried out the electronic and manual searches. XL and WB
independently inspected all candidate articles and conducted study
selection. XL and GM conducted data extraction. XL participated in the
design of the study and performed the statistical analysis. XL conceived of
the study and participated in its design and coordination and the drafted
the manuscript. All authors read and approved the final manuscript.
Acknowledgment
The study was sponsored by the Natural Science Program of Zhejiang
Department of Finance (No.: LY12H16032) and Youth Scientific Innovation
Foundation of Zhejiang Cancer Hospital (No.: QN201402).
Received: 13 March 2015 Accepted: 6 May 2015
References
1. Stupp R, Tonn JC, Brada M, Pentheroudakis G. High-grade malignant glioma:
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2010;21 Suppl 5:v190–3.
2. Huse JT, Aldape KD. The evolving role of molecular markers in the diagnosis
and management of diffuse glioma. Clin Cancer Res. 2014;20:5601–11.
Wu et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:44 Page 12 of 123. Dontu G, Liu S, Wicha MS. Stem cells in mammary development and
carcinogenesis: implications for prevention and treatment. Stem Cell Rev.
2005;1:207–13.
4. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer
revisited: the cancer stem cell hypothesis. J Clin Pharmacol. 2005;45:872–7.
5. Niero EL, Rocha-Sales B, Lauand C, Cortez BA, de Souza MM, Rezende-Teixeira P,
et al. The multiple facets of drug resistance: one history, different approaches.
J Exp Clin Cancer Res. 2014;33:37.
6. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al.
Identification of a cancer stem cell in human brain tumors. Cancer Res.
2003;63:5821–8.
7. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H.
Characterization of CD133+ hepatocellular carcinoma cells as cancer
stem/progenitor cells. Biochem Biophys Res Commun. 2006;351:820–4.
8. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, et al.
Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer.
2008;18:506–14.
9. Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A. Immunohistochemical
detection of CD133 expression in colorectal cancer: a clinicopathological
study. Cancer Sci. 2008;99:1578–83.
10. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification
and expansion of the tumorigenic lung cancer stem cell population.
Cell Death Differ. 2008;15:504–14.
11. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, et al. Nestin and CD133:
valuable stem cell-specific markers for determining clinical outcome of
glioma patients. J Exp Clin Cancer Res. 2008;27:85.
12. Ardebili SY, Zajc I, Gole B, Campos B, Herold-Mende C, Drmota S, et al.
CD133/prominin1 is prognostic for GBM patient’s survival, but inversely
correlated with cysteine cathepsins’ expression in glioblastoma derived
spheroids. Radiol Oncol. 2011;45:102–15.
13. Kase M, Minajeva A, Niinepuu K, Kase S, Vardja M, Asser T, et al. Impact of
CD133 positive stem cell proportion on survival in patients with
glioblastoma multiforme. Radiol Oncol. 2013;47:405–10.
14. Kim KJ, Lee KH, Kim HS, Moon KS, Jung TY, Jung S, et al. The presence of
stem cell marker-expressing cells is not prognostically significant in
glioblastomas. Neuropathology. 2011;31:494–502.
15. Melguizo C, Prados J, Gonzalez B, Ortiz R, Concha A, Alvarez PJ, et al.
MGMT promoter methylation status and MGMT and CD133
immunohistochemical expression as prognostic markers in glioblastoma patients
treated with temozolomide plus radiotherapy. J Transl Med. 2012;10:250.
16. Metellus P, Nanni-Metellus I, Delfino C, Colin C, Tchogandjian A, Coulibaly B,
et al. Prognostic impact of CD133 mRNA expression in 48 glioblastoma
patients treated with concomitant radiochemotherapy: a prospective
patient cohort at a single institution. Ann Surg Oncol. 2011;18:2937–45.
17. Shibahara I, Sonoda Y, Saito R, Kanamori M, Yamashita Y, Kumabe T, et al.
The expression status of CD133 is associated with the pattern and timing of
primary glioblastoma recurrence. Neuro Oncol. 2013;15:1151–9.
18. Shin JH, Lee YS, Hong YK, Kang CS. Correlation between the prognostic
value and the expression of the stem cell marker CD133 and isocitrate
dehydrogenase1 in glioblastomas. J Neurooncol. 2013;115:333–41.
19. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, et al.
Stem cell marker CD133 affects clinical outcome in glioma patients.
Clin Cancer Res. 2008;14:123–9.
20. Dahlrot RH, Hansen S, Jensen SS, Schroder HD, Hjelmborg J, Kristensen BW.
Clinical value of CD133 and nestin in patients with glioma: a population-
based study. Int J Clin Exp Pathol. 2014;7:3739–51.
21. Hatanpaa KJ, Hu T, Vemireddy V, Foong C, Raisanen JM, Oliver D, et al.
High expression of the stem cell marker nestin is an adverse prognostic
factor in WHO grade II–III astrocytomas and oligoastrocytomas.
J Neurooncol. 2014;117:183–9.
22. Milde T, Hielscher T, Witt H, Kool M, Mack SC, Deubzer HE, et al.
Nestin expression identifies ependymoma patients with poor outcome.
Brain Pathol. 2012;22:848–60.
23. Wan F, Herold-Mende C, Campos B, Centner FS, Dictus C, Becker N, et al.
Association of stem cell-related markers and survival in astrocytic gliomas.
Biomarkers. 2011;16:136–43.
24. Arai H, Ikota H, Sugawara K, Nobusawa S, Hirato J, Nakazato Y. Nestin
expression in brain tumors: its utility for pathological diagnosis and
correlation with the prognosis of high-grade gliomas. Brain Tumor Pathol.
2012;29:160–7.25. Tomao F, Papa A, Rossi L, Strudel M, Vici P, Lo Russo G, et al. Emerging role
of cancer stem cells in the biology and treatment of ovarian cancer:
basic knowledge and therapeutic possibilities for an innovative approach.
J Exp Clin Cancer Res. 2013;32:48.
26. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, et al.
AC133, a novel marker for human hematopoietic stem and progenitor cells.
Blood. 1997;90:5002–12.
27. Nosrati A, Naghshvar F, Khanari S. Cancer stem cell markers CD44, CD133 in
primary gastric adenocarcinoma. Int J Mol Cell Med. 2014;3:279–86.
28. Di C, Zhao Y. Multiple drug resistance due to resistance to stem cells and
stem cell treatment progress in cancer (Review). Exp Ther Med. 2015;9:289–93.
29. Allegra A, Alonci A, Penna G, Innao V, Gerace D, Rotondo F, et al. The
cancer stem cell hypothesis: a guide to potential molecular targets. Cancer
Invest. 2014;32:470–95.
30. Kong BH, Moon JH, Huh YM, Shim JK, Lee JH, Kim EH, et al. Prognostic
value of glioma cancer stem cell isolation in survival of primary
glioblastoma patients. Stem Cells Int. 2014;2014:838950.
31. Campos B, Herold-Mende CC. Insight into the complex regulation of CD133
in glioma. Int J Cancer. 2011;128:501–10.
32. Jin X, Jung JE, Beck S, Kim H. Cell surface Nestin is a biomarker for glioma
stem cells. Biochem Biophys Res Commun. 2013;433:496–501.
33. Fan H, Guo H, Zhang IY, Liu B, Luan L, Xu S, et al. The different HMGA1
expression of total population of glioblastoma cell line U251 and glioma
stem cells isolated from U251. Brain Res. 2011;1384:9–14.
34. Xu M, Yao Y, Hua W, Wu Z, Zhong P, Mao Y, et al. Mouse glioma
immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells.
J Neurooncol. 2014;116:497–504.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
